ArticleMetabolomics : Official journal of the Metabolomic Society2026
Plasma
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHyperlipidemia refers to the abnormal elevation in the levels of one or more plasma lipids and lipoproteins.
aimsThe purpose of this study is to examine the underlying changes in metabolic pathways associated with the lipid-lowering activity of novel carboxamide derivatives.
methodsHyperlipidemia was induced in male Wistar rats by the administration of Triton WR-1339. Carboxamide derivatives, N-(3-benzoylphenyl) - 5-nitrofuran- 2-carboxamide (Compound A) and N-(4-acetylphenyl) - 5-nitrofuran- 2-carboxamide (Compound B) were administered intragastrically and their activity was compared to the lipid-lowering drug fenofibrate. Metabolic analysis of plasma samples was done using proton nuclear magnetic resonance spectrometer equipped with a cryogenic probe. Moreover, expression levels of related genes were analyzed in liver, kidney and heart tissues using qPCR.
resultsThe tested carboxamide compounds A and B significantly reduced the elevated plasma triglycerides levels by 83% and 68%, respectively. Metabolomic analysis results revealed the impact of carboxamide compounds on the levels of 22 potential biomarkers. Carboxamide compounds partially restored the dysregulated levels of the differential metabolites and reversed the metabolic disturbance induced in hyperlipidemic rats. These results were comparable to those observed in the fenofibrate group. Carboxamide compounds activity was attributed to the regulation of not only lipid metabolism but also energy metabolism, purine metabolism and amino acid metabolism. Moreover, metabolomic results were connected to the expression of related genes in different tissues. Carboxamide compounds were able to restore gene expression levels of related genes, upregulating SDHA expression in liver, SLC13A3 and SDHA in kidney, along with upregulating SLC5A3 expression and downregulating SLC25A10 in the heart.
conclusionOverall, based on the lipid profile results and metabolic analysis supported by molecular analysis, both carboxamide derivatives showed promising lipid-lowering activity and displayed regulatory activity of metabolic pathways that were disturbed by hyperlipidemia induction. The efficacy of carboxamide compounds was comparable to the conventional lipid-lowering drug, fenofibrate. Compound A exhibited superior activity significantly lowering triglycerides levels and restoring many of the metabolic alterations induced in hyperlipidemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.